𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications

✍ Scribed by Chun-Chieh Wu; Hui-Yu Hsu; Hui-Ping Liu; John Wen-Cheng Chang; Ya-Ting Chen; Wen-Yu Hsieh; Jia-Juan Hsieh; Meng-Shu Hsieh; Yi-Rong Chen; Shiu-Feng Huang

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
513 KB
Volume
113
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Prognostic value of loss of heterozygosi
Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma
✍ Laura De Gregorio; Giacomo Manenti; Matteo Incarbone; Silvana Pilotti; Ugo Pasto πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 French βš– 89 KB

The prognostic values of loss of heterozygosity (LOH) at loci frequently involved in non-small cell lung cancer and of KRAS2 gene mutations were studied in lung adenocarcinoma patients. LOHs were relatively common, ranging from 24% at chromosome 10p to 55% at chromosome 17p13. KRAS2 mutations at cod

Clinical implication and prognostic sign
Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung
✍ Kazuya Uchino; Akihiko Ito; Tomohiko Wakayama; Yu-ichiro Koma; Tomoyo Okada; Chi πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 160 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Recently, the __TSLC1__ (tumor suppressor in lung cancer 1) gene has been identified as a novel tumor suppressor in human nonsmall cell lung carcinoma. To the authors' knowledge, the clinical relevance of __TSLC1__ gene expression has not been studied using patient data a

Somatic mutations of the APC, KRAS, and
Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas
✍ RenΓ© van Wyk; Premysl Slezak; Vanessa M. Hayes; Charles H.C.M. Buys; Maritha J. πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 113 KB πŸ‘ 2 views

Colorectal adenomas are macroscopically visible morphological changes of the mucosa that can develop focal carcinoma in the absence of surgical intervention. The successive molecular changes proposed to occur at different stages in the adenomacarcinoma sequence were primarily based on DNA studies of

TRAIL receptor upregulation and the impl
TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors
✍ Eftychia Oikonomou; Vivian Kosmidou; Anastasia Katseli; Konstantinos Kothonidis; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 French βš– 273 KB πŸ‘ 2 views

## Abstract TRAIL raises hopes as a promising anti‐tumor agent due to its selectivity toward cancer cells. Higher expression of its pro‐death receptors TRAIL‐R1 (DR4) and TRAIL‐R2 (DR5) attenuates higher sensitivity to TRAIL‐induced apoptosis, and represents a marker for better cancer prognosis and